CARTITUDE-1 evaluated ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM). We describe overall survival (OS), ≥5-year progression-free ...

JCO invites you to enter our first Art of Oncology Narrative Medicine Contest for early career oncologists. Entries will be accepted through August 31, 2025. Finalists will be judged by a panel of ...

A 2022 survey reported that 7.2% of the US population identifies as lesbian, gay, bisexual, transgender, or queer (LGBTQ+). 1 Sexual and gender minority (SGM) people experience inequity throughout the ...

Patients with ≥1 prior line of therapy were randomly assigned 1:1 to Isa OBI (1,400 mg) or IV (10 mg/kg) once weekly in cycle (C)1 and then every 2 weeks, plus pomalidomide (4 mg once daily, day ...

Pirtobrutinib, a noncovalent, Bruton tyrosine kinase inhibitor (BTKi), has shown clinical efficacy and a favorable safety profile. BRUIN CLL-321 was an open-label, randomized phase III study conducted ...

There were 262,063.05 new cases, 2,742,285.75 prevalence, 115,973.98 deaths, and 2,260,975.34 DALYs of breast cancer among older adults in 2021 in Asia. From 1990 to 2021, the ASRs of breast cancer ...

Combination therapies demonstrated enhanced benefit over single-agent immunotherapies. A decade later, combination immunotherapy with ipilimumab/nivolumab 4, 5 and relatlimab, an antilymphocyte ...

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly ...

We evaluated standardized protocol-collected data on clinical, ultrasonographic, biochemical, and pathological criteria in a multisite study of 649 suspected HCC cases in Uganda. Participants ...

Background: NIVO + RELA fixed-dose combination (FDC), compared with NIVO alone, demonstrated a clinically meaningful benefit to progression-free survival (HR 0.79, 95% CI 0.66–0.95) and overall ...

Triple-negative breast cancer (TNBC) was first described as a distinct disease entity 20 years ago. Since that time, there has been tremendous effort invested in understanding the clinical features ...

Accurate identification of the primary tumor diagnosis of patients who have undergone stereotactic radiosurgery (SRS) from electronic health records is a critical but challenging task. Traditional ...